Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.73 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.69 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27521276 | 0.89 | MAOB (0.77) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL5633862 | 0.87 | LMNA (0.73) | MAOBNR4A2LMNACYP1A2PTGS1 | |
| SCHEMBL4228288 | 0.86 | MAOB (0.73) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL29817726 | 0.86 | MAOB (0.73) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL15171108 | 0.86 | MAOB (0.73) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL11959694 | 0.85 | MAOB (0.72) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL2559641 | 0.85 | MAOB (0.67) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL4552204 | 0.84 | MAOB (0.71) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL1379497 | 0.84 | MAOB (1.00) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL22874674 | 0.84 | MAOB (0.71) | MAOBNR4A2PARP10MAOALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3760633-B1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2021-12-15 | — | — | EP | disclosed |
| WO-2019170088-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | 北京赛特明强医药科技有限公司 | 2019-09-12 | — | — | WO | disclosed |
| EP-2036878-B1 | PROCESS FOR PRODUCTION OF ALCOHOL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2012-08-22 | — | — | EP | disclosed |
| US-7745669-B2 | Process for production of alcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-29 | — | — | US | disclosed |
| CN-100554244-C | New MAO-B inhibitor | HOFFMANN LA ROCHE (CH) | 2009-10-28 | — | — | CN | disclosed |
| US-20090259074-A1 | PROCESS FOR PRODUCTION OF ALCOHOL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-10-15 | — | — | US | disclosed |
| US-7598266-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-7544707-B2 | Bicyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| EP-2036878-A1 | PROCESS FOR PRODUCTION OF ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | CONNER SCOTT EUGENE | 2009-02-26 | — | — | US | disclosed |
| WO-2006000324-A2 | NEW MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288367-A1 | Benzyloxy derivatives as MAOB inhibitors | HOFFMAN-LA ROCHE INC. | 2005-12-29 | — | — | US | disclosed |
| EP-1585726-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2005066136-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005019151-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2004063155-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-1984000106-A1 | ANESTHETIC-ANTIPRURITIC N-(3-(4-(3-FLUOROBENZYLOXY)PHENOXY)PROPYL)MORPHOLINE COMPOUNDS, COMPOSITIONS AND USE | STIEFEL LABORATORIES (US) | 1984-01-19 | — | — | WO | disclosed |
| WO-1984000106-A1 | ANESTHETIC-ANTIPRURITIC N-(3-(4-(3-FLUOROBENZYLOXY)PHENOXY)PROPYL)MORPHOLINE COMPOUNDS, COMPOSITIONS AND USE | STIEFEL LABORATORIES (US) | 1984-01-19 | — | — | WO | disclosed |
| US-4393061-A | Anesthetic-antipruritic morpholine compounds, compositions and use | STIEFEL LABORATORIES, INC. (US) | 1983-07-12 | — | — | US | disclosed |
| US-4393061-A | Anesthetic-antipruritic morpholine compounds, compositions and use | STIEFEL LABORATORIES, INC. (US) | 1983-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288367-A1 | Benzyloxy derivatives as MAOB inhibitors | MAOB, MAOA, COMT | MAOB 1/4885NR4A2 1668/4885PARP10 1329/4885 |
| US-20090054479-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | PPARA, PPARG, PPARD | MAOB 1278/4885NR4A2 48/4885PARP10 3393/4885 |
| US-20090259074-A1 | PROCESS FOR PRODUCTION OF ALCOHOL COMPOUND | XDH, ADH5, ADH1A | MAOB 499/4885NR4A2 835/4885PARP10 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.